User: Guest

MYASTHENIA GRAVIS DRUGS

Global Market Trajectory & Analytics

MCP13519

VALIDATED EXECUTIVE ENGAGEMENTS

OUTREACH

2999
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

542
Interactions with Platform & by Email

PARTICIPANTS

92
Unique # Participated

VALIDATIONS

41
Responses Validated*
* Login to view program details and full enterprise executive list.

DATE

JUL 2020

TABLES

57

PAGES

125

EDITION

8

PRICE

USD $4950

Amid the COVID-19 crisis, the global market for Myasthenia Gravis Drugs estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2027, growing at a CAGR of 8.7% over the analysis period 2020-2027. Drug Treatment, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Rapid Immunotherapies segment is readjusted to a revised 6.9% CAGR for the next 7-year period.
The Myasthenia Gravis Drugs market in the U.S. is estimated at US$372.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$391.6 Million by the year 2027 trailing a CAGR of 8.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.
In the global Thymectomy segment, USA, Canada, Japan, China and Europe will drive the 10.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$195.8 Million in the year 2020 will reach a projected size of US$401.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$260.7 Million by the year 2027.We bring years of research experience to this 8th edition of our report. The 125-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Alexion Pharmaceuticals, Inc.; Bausch Health Companies, Inc.; Catalyst Pharmaceuticals, Inc.; CSL Limited; Curavac Inc.; Cytokinetics, Inc.; F. Hoffmann-La Roche AG; Flamel Technologies S.A.; Galenica Ltd.; GlaxoSmithKline PLC; Grifols SA; Lupin Pharmaceuticals, Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis International AG; Pfizer, Inc.; Shire PLC
» Treatment (Drug Treatment, Rapid Immunotherapies, Thymectomy)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

ACTIVE CLIENT

INACTIVE CLIENT

ACTIVE PANELIST

INACTIVE PANELIST

OPT-INS

FEATURED COMPANIES

YOUR PRIVACY MATTERS!

Registration is required to access our data stacks.

WORLD BRANDS

YOUR PRIVACY MATTERS!

Registration is required to access our data stacks.

EXECUTIVES ENGAGED

YOUR PRIVACY MATTERS!

Registration is required to access our data stacks.

KEY DIFFERENTIATORS

We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.

* A review of 262 off-the-shelf market report publishers worldwide.

WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.

Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.

Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)

A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.

Where relevent and possible we present competitive brands.

Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.

Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.

Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.

We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.

  
05
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Global Competitor Market Shares
Myasthenia Gravis Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Myasthenia Gravis Drugs Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027
Myasthenia Gravis Drugs Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019
Myasthenia Gravis Drugs Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027
Drug Treatment (Treatment) World Market by Region/Country in US$ Thousand: 2020 to 2027
Drug Treatment (Treatment) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019
Drug Treatment (Treatment) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027
Rapid Immunotherapies (Treatment) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027
Rapid Immunotherapies (Treatment) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019
Rapid Immunotherapies (Treatment) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027
Thymectomy (Treatment) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027
Thymectomy (Treatment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019
Thymectomy (Treatment) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Myasthenia Gravis Drugs Market Share (in %) by Company: 2019 & 2025
United States Myasthenia Gravis Drugs Market Estimates and Projections in US$ Thousand by Treatment: 2020 to 2027
Myasthenia Gravis Drugs Market in the United States by Treatment: A Historic Review in US$ Thousand for 2012-2019
United States Myasthenia Gravis Drugs Market Share Breakdown by Treatment: 2012 VS 2020 VS 2027
CANADA
Canadian Myasthenia Gravis Drugs Market Estimates and Forecasts in US$ Thousand by Treatment: 2020 to 2027
Canadian Myasthenia Gravis Drugs Historic Market Review by Treatment in US$ Thousand: 2012-2019
Myasthenia Gravis Drugs Market in Canada: Percentage Share Breakdown of Sales by Treatment for 2012, 2020, and 2027
JAPAN
Japanese Market for Myasthenia Gravis Drugs: Annual Sales Estimates and Projections in US$ Thousand by Treatment for the Period 2020-2027
Myasthenia Gravis Drugs Market in Japan: Historic Sales Analysis in US$ Thousand by Treatment for the Period 2012-2019
Japanese Myasthenia Gravis Drugs Market Share Analysis by Treatment: 2012 VS 2020 VS 2027
CHINA
Chinese Myasthenia Gravis Drugs Market Growth Prospects in US$ Thousand by Treatment for the Period 2020-2027
Myasthenia Gravis Drugs Historic Market Analysis in China in US$ Thousand by Treatment: 2012-2019
Chinese Myasthenia Gravis Drugs Market by Treatment: Percentage Breakdown of Sales for 2012, 2020, and 2027
EUROPE
Market Facts & Figures
European Myasthenia Gravis Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
European Myasthenia Gravis Drugs Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027
Myasthenia Gravis Drugs Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019
European Myasthenia Gravis Drugs Market Share Shift by Region/Country: 2012 VS 2020 VS 2027
European Myasthenia Gravis Drugs Market Estimates and Forecasts in US$ Thousand by Treatment: 2020-2027
Myasthenia Gravis Drugs Market in Europe in US$ Thousand by Treatment: A Historic Review for the Period 2012-2019
European Myasthenia Gravis Drugs Market Share Breakdown by Treatment: 2012 VS 2020 VS 2027
FRANCE
Myasthenia Gravis Drugs Market in France by Treatment: Estimates and Projections in US$ Thousand for the Period 2020-2027
French Myasthenia Gravis Drugs Historic Market Scenario in US$ Thousand by Treatment: 2012-2019
French Myasthenia Gravis Drugs Market Share Analysis by Treatment: 2012 VS 2020 VS 2027
GERMANY
Myasthenia Gravis Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Treatment for the Period 2020-2027
German Myasthenia Gravis Drugs Historic Market Analysis in US$ Thousand by Treatment: 2012-2019
German Myasthenia Gravis Drugs Market Share Breakdown by Treatment: 2012 VS 2020 VS 2027
ITALY
Italian Myasthenia Gravis Drugs Market Growth Prospects in US$ Thousand by Treatment for the Period 2020-2027
Myasthenia Gravis Drugs Historic Market Analysis in Italy in US$ Thousand by Treatment: 2012-2019
Italian Myasthenia Gravis Drugs Market by Treatment: Percentage Breakdown of Sales for 2012, 2020, and 2027
UNITED KINGDOM
United Kingdom Market for Myasthenia Gravis Drugs: Annual Sales Estimates and Projections in US$ Thousand by Treatment for the Period 2020-2027
Myasthenia Gravis Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Treatment for the Period 2012-2019
United Kingdom Myasthenia Gravis Drugs Market Share Analysis by Treatment: 2012 VS 2020 VS 2027
REST OF EUROPE
Rest of Europe Myasthenia Gravis Drugs Market Estimates and Forecasts in US$ Thousand by Treatment: 2020-2027
Myasthenia Gravis Drugs Market in Rest of Europe in US$ Thousand by Treatment: A Historic Review for the Period 2012-2019
Rest of Europe Myasthenia Gravis Drugs Market Share Breakdown by Treatment: 2012 VS 2020 VS 2027
ASIA-PACIFIC
Myasthenia Gravis Drugs Market in Asia-Pacific by Treatment: Estimates and Projections in US$ Thousand for the Period 2020-2027
Asia-Pacific Myasthenia Gravis Drugs Historic Market Scenario in US$ Thousand by Treatment: 2012-2019
Asia-Pacific Myasthenia Gravis Drugs Market Share Analysis by Treatment: 2012 VS 2020 VS 2027
REST OF WORLD
Rest of World Myasthenia Gravis Drugs Market Estimates and Forecasts in US$ Thousand by Treatment: 2020 to 2027
Rest of World Myasthenia Gravis Drugs Historic Market Review by Treatment in US$ Thousand: 2012-2019
Myasthenia Gravis Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Treatment for 2012, 2020, and 2027
IV. COMPETITION
Total Companies Profiled : 38

Click here to request a full table of contents and more details on this project.

V. CURATED RESEARCH

INSIDER ACCESS TO

 METHODOLOGY  QUESTIONNAIRE  INFLUENCER NETWORK
YOUR PRIVACY MATTERS!

Registration is required to access our data stacks.

RESEARCH PANEL

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.

  • Complimentary previews of full stack research data for participated
  • Insider access to research programs including engagements and stats from other panelists
  • Unlimited research credits of $1000 per participated project
  • Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
  • Interact with other panelists via our MarketGlassTM Data Exchange Platform*
  • BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*

* Complete details will be shared with panelists upon formal acceptance.

 GLOBAL EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

© Global Industry Analysts, Inc., USA. All Rights Reserved.